Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
Key Highlights
- ➤REO 033 randomized Phase 2 will enroll 30 patients per treatment arm
- ➤Pelareorep combination is being tested against FOLFIRI plus bevacizumab standard of care
- ➤Primary endpoint is objective response rate, with survival and safety secondary endpoints
- ➤FDA interactions could support a pivotal expansion targeting accelerated and full approval
- ➤REO 022 outcomes more than doubled versus historical treatment results
Expert Statements
Sanjay Goel, M.D., M.S., FASCO, Professor of Medicine at Rutgers Cancer Institute and Lead Investigator
“I am thrilled to see the recent momentum in the REO 033 study among sites, physicians, and patients”
Sanjay Goel, M.D., M.S., FASCO, Professor of Medicine at Rutgers Cancer Institute and Lead Investigator
“Having been involved in the REO 022 study, I have a strong conviction that pelareorep can positively impact patients in a meaningful way, and this controlled randomized study will help prove that out.”
Jared Kelly, Chief Executive Officer of Oncolytics
“Second-line mCRC development is generally stalling because emerging therapies are not working well, especially in RAS-mutant MSS patients.”
Jared Kelly, Chief Executive Officer of Oncolytics
“With mCRC growing faster than almost every cancer in the U.S. and only minimally effective options for second-line patients, pelareorep has the potential in this controlled study to change the standard of care by improving what has been in place for the better part of a decade.”
Jared Kelly, Chief Executive Officer of Oncolytics
“It’s a multi-billion-dollar market that is being largely ignored because nothing works better than the standard of care.”
Jared Kelly, Chief Executive Officer of Oncolytics
“Adding pelareorep to the standard of care could double the efficacy while maintaining an acceptable safety profile.”
Jared Kelly, Chief Executive Officer of Oncolytics
“This is what drug development is all about.”
SAN DIEGO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech(®) Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the Company is presenting a trial-in-progress abstract and e-poster discussing the REO 033 study at the European Society for Medical Oncology (“ESMO”) Congress 2026. REO 033 is a randomized study evaluating pelareorep in combination with folinic acid, fluorouracil, and irinotecan (“FOLFIRI”) and bevacizumab versus standard-of-care FOLFIRI and bevacizumab as second-line treatment for RAS-mutant, microsatellite-stable (“MSS”) metastatic colorectal cancer (“mCRC”) patients (link to study on ClinicalTrials.gov). The study is designed to validate the encouraging efficacy signals observed in REO 022 while generating the controlled clinical data necessary to support future regulatory interactions and potential registration.
Get started
Create a free account to read the full story.